Targeting beta-cell cyclic 3'5' adenosine monophosphate for the development of novel drugs for treating type 2 diabetes mellitus. A review (Q35962745)

11 August 2017

1 reference

title

Targeting beta-cell cyclic 3'5' adenosine monophosphate for the development of novel drugs for treating type 2 diabetes mellitus. A review (English)

1 reference

11 August 2017

1 reference

Brian Furman

1 reference

11 August 2017

Nigel Pyne

series ordinal

1 reference

11 August 2017

Peter Flatt

series ordinal

1 reference

11 August 2017

Finbarr O'Harte

series ordinal

1 reference

11 August 2017

publication date

1 December 2004

1 reference

Journal of Pharmacy and Pharmacology

11 August 2017

published in

1 reference

11 August 2017

1 reference

11 August 2017

1 reference

11 August 2017

page(s)

1477-1492

1 reference

Effect of type-selective inhibitors on cyclic nucleotide phosphodiesterase activity and insulin secretion in the clonal insulin secreting cell line BRIN-BD11.

11 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Inhibition of dipeptidyl peptidase IV improves metabolic control over a 4-week study period in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

ACTH stimulates insulin secretion from MIN6 cells and primary mouse and human islets of Langerhans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Relationship between plasma plasminogen activator inhibitor 1 and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Rapid activation and nuclear translocation of mitogen-activated protein kinases in response to physiological concentration of glucose in the MIN6 pancreatic beta cell line.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Inhibitors of phosphodiesterase isoforms III or IV suppress islet-cell nitric oxide production

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Feedback regulation of glucose-dependent insulinotropic polypeptide (GIP) secretion by insulin in conscious rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Long-lasting antidiabetic effect of a dipeptidyl peptidase IV-resistant analog of glucagon-like peptide-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Glucagon-like peptide 1 induces pancreatic beta-cell proliferation via transactivation of the epidermal growth factor receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

The effect of cyclic adenosine monophosphate on the mitogen-activated protein kinase pathway depends on both the cell type and the type of tyrosine kinase-receptor

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

The GLP-1 derivative NN2211 restores beta-cell sensitivity to glucose in type 2 diabetic patients after a single dose

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Is the Fischer 344/CRJ rat a protein-knock-out model for dipeptidyl peptidase IV-mediated lung metastasis of breast cancer?

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Cloning of dog heart PDE1A - a first detailed characterization at the molecular level in this species

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Cyclic GMP phosphodiesterase-5: target of sildenafil

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1 which have extended metabolic stability and improved biological activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Preservation of active incretin hormones by inhibition of dipeptidyl peptidase IV suppresses meal-induced incretin secretion in dogs

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Type VIII adenylyl cyclase in rat beta cells: coincidence signal detector/generator for glucose and GLP-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Forskolin suppresses insulin gene transcription in islet beta-cells through a protein kinase A-independent pathway

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Insertion of an N-terminal 6-aminohexanoic acid after the 7 amino acid position of glucagon-like peptide-1 produces a long-acting hypoglycemic agent.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Enhancing Incretin Action for the Treatment of Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Benzyl vinylogous amide substituted aryldihydropyridazinones and aryldimethylpyrazolones as potent and selective PDE3B inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

The insulinotropic effect of acute exendin-4 administered to humans: comparison of nondiabetic state to type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Effects of 1-mo bolus subcutaneous administration of exendin-4 in type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Glucose-dependent insulinotropic polypeptide activates the Raf-Mek1/2-ERK1/2 module via a cyclic AMP/cAMP-dependent protein kinase/Rap1-mediated pathway.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

The effect of selective phosphodiesterase inhibitors on plasma insulin concentrations and insulin secretion in vitro in the rat.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Phosphorylation-dependent nucleocytoplasmic shuttling of pancreatic duodenal homeobox-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Characterization of GIP(1-30) and GIP(1-42) as stimulators of proinsulin gene transcription

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Plasma glucagon-like peptide-1 (GLP-1) responses to duodenal fat and glucose infusions in lean and obese men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

The neuropeptide pituitary adenylate cyclase-activating polypeptide and islet function

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Isolation and characterization of PDE9A, a novel human cGMP-specific phosphodiesterase

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Evidence that the major degradation product of glucose-dependent insulinotropic polypeptide, GIP(3-42), is a GIP receptor antagonist in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Enhanced cAMP generation and insulin-releasing potency of two novel Tyr1-modified enzyme-resistant forms of glucose-dependent insulinotropic polypeptide is associated with significant antihyperglycaemic activity in spontaneous obesity-diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Characterization of the cellular and metabolic effects of a novel enzyme-resistant antagonist of glucose-dependent insulinotropic polypeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Cyclic AMP production and insulin releasing activity of synthetic fragment peptides of glucose-dependent insulinotropic polypeptide.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Glucose-dependent insulinotropic polypeptide analogues and their therapeutic potential for the treatment of obesity-diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Improved biological activity of Gly2- and Ser2-substituted analogues of glucose-dependent insulinotrophic polypeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Effects of the novel (Pro3)GIP antagonist and exendin(9-39)amide on GIP- and GLP-1-induced cyclic AMP generation, insulin secretion and postprandial insulin release in obese diabetic (ob/ob) mice: evidence that GIP is the major physiological increti

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8-substituted GLP-1 analogues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Lys9 for Glu9 substitution in glucagon-like peptide-1(7-36)amide confers dipeptidylpeptidase IV resistance with cellular and metabolic actions similar to those of established antagonists glucagon-like peptide-1(9-36)amide and exendin (9-39).

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

The calcium/calmodulin-dependent phosphodiesterase PDE1C down-regulates glucose-induced insulin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Important role of phosphodiesterase 3B for the stimulatory action of cAMP on pancreatic beta-cell exocytosis and release of insulin

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Beta-cell-targeted overexpression of phosphodiesterase 3B in mice causes impaired insulin secretion, glucose intolerance, and deranged islet morphology

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Glucagon-like peptide-I-(7-37) suppresses hyperglycemia in rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Identification of a bioactive domain in the amino-terminus of glucose-dependent insulinotropic polypeptide (GIP).

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Dipeptidyl peptidase IV-resistant [D-Ala(2)]glucose-dependent insulinotropic polypeptide (GIP) improves glucose tolerance in normal and obese diabetic rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

[Ser2]- and [SerP2] incretin analogs: comparison of dipeptidyl peptidase IV resistance and biological activities in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Implementation of GLP-1 based therapy of type 2 diabetes mellitus using DPP-IV inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Treatment of type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Epac: A new cAMP-binding protein in support of glucagon-like peptide-1 receptor-mediated signal transduction in the pancreatic beta-cell

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Signal transduction crosstalk in the endocrine system: pancreatic beta-cells and the glucose competence concept

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Glucagon-Like Peptide-1 Synthetic Analogs: New Therapeutic Agents for Use in the Treatment of Diabetes Mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

cAMP-dependent mobilization of intracellular Ca2+ stores by activation of ryanodine receptors in pancreatic beta-cells. A Ca2+ signaling system stimulated by the insulinotropic hormone glucagon-like peptide-1-(7-37)

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Regulation of insulin secretion: the role of second messengers.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Glucagon receptors on human islet cells contribute to glucose competence of insulin release

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

In situ activation of the type 2 ryanodine receptor in pancreatic beta cells requires cAMP-dependent phosphorylation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

High glucose stimulates early response gene c-Myc expression in rat pancreatic beta cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of Type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

cAMP-regulated guanine nucleotide exchange factor II (Epac2) mediates Ca2+-induced Ca2+ release in INS-1 pancreatic beta-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Epac-selective cAMP analog 8-pCPT-2'-O-Me-cAMP as a stimulus for Ca2+-induced Ca2+ release and exocytosis in pancreatic beta-cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Intracellular cAMP potentiates voltage-dependent activation of L-type Ca2+ channels in rat islet beta-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Critical role of cAMP-GEFII--Rim2 complex in incretin-potentiated insulin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

cAMP effector mechanisms. Novel twists for an 'old' signaling system

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Glucagon-like peptide-1 7-36: a physiological incretin in man.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Expression of adenylyl cyclase subtypes in pancreatic beta-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Anchoring of protein kinase A facilitates hormone-mediated insulin secretion

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Expression of cyclic GMP-inhibited phosphodiesterases 3A and 3B (PDE3A and PDE3B) in rat tissues: differential subcellular localization and regulated expression by cyclic AMP

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Heterotrimeric G-proteins are implicated in the regulation of apoptosis in pancreatic beta-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Pancreatic preproglucagon cDNA contains two glucagon-related coding sequences arranged in tandem

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Effect of small intestinal nutrient infusion on appetite, gastrointestinal hormone release, and gastric myoelectrical activity in young and older men.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Structure-function analysis of a series of novel GIP analogues containing different helical length linkers

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Cyclic nucleotide phosphodiesterases and their role in endocrine cell signaling.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Effects of 3 Months of Continuous Subcutaneous Administration of Glucagon-Like Peptide 1 in Elderly Patients With Type 2 Diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Dipeptidyl-peptidase IV (CD26)--role in the inactivation of regulatory peptides

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Inhibition of gastric inhibitory polypeptide signaling prevents obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Insulinotropin: glucagon-like peptide I (7-37) co-encoded in the glucagon gene is a potent stimulator of insulin release in the perfused rat pancreas

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Amino terminal glycation of gastric inhibitory polypeptide enhances its insulinotropic action on clonal pancreatic B-cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

NH2-terminally modified gastric inhibitory polypeptide exhibits amino-peptidase resistance and enhanced antihyperglycemic activity.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Improved glycaemic control in obese diabetic ob/ob mice using N-terminally modified gastric inhibitory polypeptide

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Degradation and glycemic effects of His(7)-glucitol glucagon-like peptide-1(7-36)amide in obese diabetic ob/ob mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Improved stability, insulin-releasing activity and antidiabetic potential of two novel N-terminal analogues of gastric inhibitory polypeptide: N-acetyl-GIP and pGlu-GIP.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Effect of oral milrinone on mortality in severe chronic heart failure. The PROMISE Study Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Modulation of Insulin Secretion and Glycemia by Selective Inhibition of Cyclic AMP Phosphodiesterase III

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Enhanced glucose-dependent insulinotropic polypeptide secretion and insulinotropic action in glucagon-like peptide 1 receptor -/- mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Glucose-stimulated insulin secretion is not dependent on activation of protein kinase A.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Inhibition of insulin secretion via distinct signaling pathways in alpha2-adrenoceptor knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Molecular characterization of human and bovine rod photoreceptor cGMP phosphodiesterase alpha-subunit and chromosomal localization of the human gene

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

beta-cell dysfunction and failure in type 2 diabetes: potential mechanisms.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and beta-cell glucose responsiveness in VDF (fa/fa) Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Long-term treatment with dipeptidyl peptidase IV inhibitor improves hepatic and peripheral insulin sensitivity in the VDF Zucker rat: a euglycemic-hyperinsulinemic clamp study

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Dipeptidyl peptidase IV inhibitor treatment stimulates beta-cell survival and islet neogenesis in streptozotocin-induced diabetic rats.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Gluco-incretins control insulin secretion at multiple levels as revealed in mice lacking GLP-1 and GIP receptors

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

The insulin- and glucagon-stimulated 'dense-vesicle' high-affinity cyclic AMP phosphodiesterase from rat liver. Purification, characterization and inhibitor sensitivity

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Distinctive anatomical patterns of gene expression for cGMP-inhibited cyclic nucleotide phosphodiesterases

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

The long-acting GLP-1 derivative NN2211 ameliorates glycemia and increases beta-cell mass in diabetic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Factors determining the glucose sensitivity and glucose responsiveness of pancreatic beta cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Identification of glucagon-like peptide 1 (GLP-1) actions essential for glucose homeostasis in mice with disruption of GLP-1 receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Effects of type-selective phosphodiesterase inhibitors on glucose-induced insulin secretion and islet phosphodiesterase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

The Adenylate cyclase-cyclic AMP system in islets of langerhans and its role in the control of insulin release

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Glucagon-like peptide 1 stimulates insulin gene promoter activity by protein kinase A-independent activation of the rat insulin I gene cAMP response element

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Regulation of cAMP and cGMP signaling: new phosphodiesterases and new functions

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Chronic inhibition of circulating dipeptidyl peptidase IV by FE 999011 delays the occurrence of diabetes in male zucker diabetic fatty rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Cyclic nucleotide phosphodiesterase of rat pancreatic islets. Effects of Ca2+, calmodulin and trifluoperazine

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. The Diabetes Control and Complications Trial Research Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Expression cloning of the pancreatic beta cell receptor for the gluco-incretin hormone glucagon-like peptide 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Phosphodiesterase isozymes: molecular targets for novel antiasthma agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

The U.K. Prospective Diabetes Study. A review

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Gastric inhibitory polypeptide receptor, a member of the secretin-vasoactive intestinal peptide receptor family, is widely distributed in peripheral organs and the brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Glucagon-like peptide 1: a potent glycogenic hormone

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Incretins, insulin secretion and Type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

GIP regulates glucose transporters, hexokinases, and glucose-induced insulin secretion in RIN 1046-38 cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Biological activities of glucagon-like peptide-1 analogues in vitro and in vivo

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Molecular cloning and characterization of a calmodulin-dependent phosphodiesterase enriched in olfactory sensory neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Glucagon-like peptide 1 stimulates lipolysis in clonal pancreatic beta-cells (HIT).

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Attenuation of insulin secretion by insulin-like growth factor 1 is mediated through activation of phosphodiesterase 3B.

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Glucagon-like peptide-1 promotes DNA synthesis, activates phosphatidylinositol 3-kinase and increases transcription factor pancreatic and duodenal homeobox gene 1 (PDX-1) DNA binding activity in beta (INS-1)-cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Adaptation in cyclic AMP signalling processes: A central role for cyclic AMP phosphodiesterases

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

Truncated glucagon-like peptide I, an insulin-releasing hormone from the distal gut

21 January 2018

1 reference

https://api.crossref.org/works/10.1211%2F0022357044805

21 January 2018

Identifiers

DOI

10.1211/0022357044805

1 reference

11 August 2017

1 reference